Global Zykadia (Ceritinib; Novartis) Drug Overview & Outlook 2017-2026: A Tyrosine Kinase Inhibitor that Targets Anaplastic Lymphoma Kinase (ALK)
Dublin, July 05, 2019 (GLOBE NEWSWIRE) -- The "Zykadia" report has been added to ResearchAndMarkets.com's offering.
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4.
This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3-5% of all NSCLC cases.
Key Topics Covered
- Drug Overview
- Product Profiles
- Zykadia : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
Figure 1: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 2: The authors drug assessment summary for ensartinib in non-small cell lung cancer
LIST OF TABLES
Table 1: Zykadia drug profile
Table 2: Zykadia pivotal trial data in non-small cell lung cancer
Table 3: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/z0m2k5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
